Shared Immune-Inflammatory Gene Networks and Drug Predictions for PCOS and T2DM

A bioinformatics study from 2026 identifies 239 common differentially expressed genes (140 upregulated, 99 downregulated) between polycystic ovary syndrome (PCOS) and type 2 diabetes mellitus (T2DM). The work, authored by Xuemeng Liu and shared on figshare, analyzes microarray datasets from the GEO database to identify nine hub genes and predict 40 potential therapeutic drugs.

Use Cases

• Identifying shared immune-inflammatory pathways between PCOS and T2DM based on the 239 common differentially expressed genes.
• Predicting potential therapeutic drugs based on the identified hub genes (e.g., ITGAM, ITGB2, CCR5).
• Constructing transcription factor and miRNA regulatory networks based on the nine identified hub genes.
• Validating bioinformatics findings through experimental methods like RT-qPCR, as described in the study.

Strengths

• Identifies 239 common differentially expressed genes between two diseases.
• Predicts 40 potential therapeutic drugs based on hub gene analysis.
• Results include experimental validation via RT-qPCR for nine hub genes.
• Dataset is openly licensed under CC-BY-4.0.

Limitations

• Row count and column-level documentation are unknown.
• The 19.7 KB file size suggests a limited scope, likely containing summary results rather than raw expression data.
• Freshness should be verified as the last update is dated 2026-04-16.

Provenance

Source

Gene Expression Omnibus (GEO) database, datasets GSE34526 and GSE25724.

Collection Method

Bioinformatics analysis using R packages (limma, clusterProfiler) and Cytoscape for network construction.

Time Range

Temporal coverage of the source microarray datasets is not specified.

Freshness

Last updated 2026-04-16 05:25:48.

Geography

Spatial coverage is not specified.